IQV vs. ZTS: IQVIA vs. Zoetis Stock Comparison

November 11, 2026

How do IQVIA (IQV) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

IQVIA (IQV) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but IQV is classified in Life Sciences Tools & Services while ZTS is classified in Pharmaceuticals.

Company profile comparison for IQVIA (IQV) and Zoetis (ZTS)
Profile Item	IQV	ZTS
Name	IQVIA Holdings Inc.	Zoetis Inc. Class A Common Stock
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Pharmaceuticals
GICS Sub-Industry	Life Sciences Tools & Services	Pharmaceuticals
Market Capitalization	44.80 billion USD	32.26 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	May 9, 2013	February 1, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

IQV

ZTS

GSPC

IQVIA (IQV) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for IQVIA (IQV) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for IQVIA (IQV) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
Total Return (1Y)	32.11%	-30.10%
Total Return (3Y, Annualized)	13.15%	-20.42%
Total Return (5Y, Annualized)	2.00%	-16.87%

Risk Profile

Drawdown History

IQV

ZTS

GSPC

IQVIA (IQV) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for IQVIA (IQV) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
Volatility (1Y, Annualized)	40.77%	38.23%
Beta (5Y)	1.14	0.66
Max Drawdown (5Y)	-51.52%	-70.45%
Avg. Volume (3M)	1.40M	4.65M

Risk-Adjusted Performance

Risk-Return Positioning

IQV and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
Sharpe Ratio (1Y)	0.68	-0.90
Sortino Ratio (1Y)	1.03	-1.10

Profitability

ROE (TTM)

Both IQVIA (IQV) at 21.39% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.39%

Max: 109.18%
IQV: 21.39%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max: 109.18%
ZTS: 57.63%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Zoetis (ZTS) at 26.41% keeps the most of each sales dollar — above its industry’s net margin range — and IQVIA (IQV) at 8.05% also retains a top-quartile share.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.05%

Max: 18.05%
IQV: 8.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS: 26.41%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Zoetis (ZTS) at 38.19% operates in the top operating margin quartile, ahead of IQVIA (IQV) at 13.73%, which runs around its industry’s norm.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.73%

Max: 83.12%
Q3: 14.77%
IQV: 13.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max: 83.12%
ZTS: 38.19%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
ROE (TTM)	21.39%	57.63%
ROA (TTM)	5.08%	14.87%
Net Margin (TTM)	8.05%	26.41%
Operating Margin (TTM)	13.73%	38.19%
Gross Margin (TTM)	33.07%	71.65%

Growth

Revenue Growth

Both IQVIA (IQV) at 5.87% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both IQVIA (IQV) at 4.67% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
Revenue Growth (YoY)	5.87%	2.28%
Revenue Growth (3Y CAGR)	4.21%	5.42%
EPS Growth (YoY)	4.67%	10.05%
EPS Growth (3Y CAGR)	11.08%	10.27%

Financial Strength

Current Ratio (MRQ)

Both IQVIA (IQV) at 0.83 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
IQV: 0.83
Min: 0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ZTS: 2.35
Min: 0.10

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Debt sits unusually high against shareholders’ equity for both IQVIA (IQV) at 2.40 and Zoetis (ZTS) at 2.80 — each debt-to-equity ratio is above its industry benchmark range.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40

IQV: 2.40
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS: 2.80
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
Current Ratio (MRQ)	0.83	2.35
Debt / Equity (MRQ)	2.40	2.80
Net Debt / EBITDA	4.46	1.92

Dividends

Dividend Yield (TTM)

IQVIA (IQV) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS: 2.55%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

IQVIA (IQV) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

IQV: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS: 35.24%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
Dividend Yield (TTM)	0.00%	2.55%
Dividend Payout Ratio (TTM)	0.00%	35.24%

Valuation

P/E Ratio (TTM)

Both IQVIA (IQV) at 33.07 and Zoetis (ZTS) at 13.50 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.07

Max: 85.34
Q3: 43.46
IQV: 33.07
Median: 26.69
Q1: 13.30
Min: 0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max: 85.34
Q3: 43.46
Median: 26.69
ZTS: 13.50
Q1: 13.30
Min: 0.07

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

IQVIA (IQV) at 2.59 sits in the cheaper P/S ratio quartile while Zoetis (ZTS) at 3.40 prices around its industry’s middle — IQV costs less per dollar of sales, though read it alongside growth and margins.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.59

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
IQV: 2.59
Min: 0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max: 58.18
Q3: 25.77
Median: 7.30
ZTS: 3.40
Q1: 3.01
Min: 0.01

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both IQVIA (IQV) at 6.73 and Zoetis (ZTS) at 9.80 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

IQV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.73

Max: 13.53
IQV: 6.73
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max: 13.53
ZTS: 9.80
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

IQVIA (IQV) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for IQVIA (IQV) and Zoetis (ZTS)
Metric	IQV	ZTS
P/E Ratio (TTM)	33.07	13.50
P/S Ratio (TTM)	2.59	3.40
P/B Ratio (MRQ)	6.73	9.80
Free Cash Flow Yield (TTM)	4.72%	6.36%